Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics

Dow Jones07-24

By Chris Wack

Pieris Pharmaceuticals shares doubled to $16.06 after the company said it was being bought by Palvella Therapeutics, a clinical-stage biopharmaceutical company.

The combined company will focus on developing and commercializing Palvella's lead clinical product candidate, Qtorin 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations and other serious, functionally debilitating skin diseases.

Upon completion of the proposed merger, the combined company will operate under the name Palvella Therapeutics, will be headquartered in Wayne, Pa., and is expected to trade on the Nasdaq Capital Market.

In connection with the proposed merger, Palvella has secured commitments from a syndicate of leading healthcare-dedicated investors in an oversubscribed $78.9 million concurrent private financing.

The combined company is expected to have $80.5 million of cash and cash equivalents at closing of the proposed merger. These cash resources are expected to be used to advance Qtorin through multiple clinical data milestones and are expected to fund the combined company's operations into the second half of 2027.

The proposed merger is expected to close in the fourth quarter of 2024. Pieris stockholders are expected to own 18% of the combined company and pre-merger Palvella stockholders are expected to own 82% of the combined company

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 24, 2024 09:54 ET (13:54 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453088893?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-24 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453088893","market":"nz","top_or_hot":-1,"title":"Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n   Pieris Pharmaceuticals shares doubled to $16.06 after the company said it was being bought by Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a clinical-stage biopharmaceutical company. \n</p>\n<p>\n  The combined company will focus on developing and commercializing Palvella's lead clinical product candidate, Qtorin 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations and other serious, functionally debilitating skin diseases. \n</p>\n<p>\n  Upon completion of the proposed merger, the combined company will operate under the name Palvella Therapeutics, will be headquartered in Wayne, Pa., and is expected to trade on the Nasdaq Capital Market. \n</p>\n<p>\n  In connection with the proposed merger, Palvella has secured commitments from a syndicate of leading healthcare-dedicated investors in an oversubscribed $78.9 million concurrent private financing. \n</p>\n<p>\n  The combined company is expected to have $80.5 million of cash and cash equivalents at closing of the proposed merger. These cash resources are expected to be used to advance Qtorin through multiple clinical data milestones and are expected to fund the combined company's operations into the second half of 2027. \n</p>\n<p>\n   The proposed merger is expected to close in the fourth quarter of 2024. Pieris stockholders are expected to own 18% of the combined company and pre-merger Palvella stockholders are expected to own 82% of the combined company \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2024 09:54 ET (13:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-24 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n   Pieris Pharmaceuticals shares doubled to $16.06 after the company said it was being bought by Palvella Therapeutics, a clinical-stage biopharmaceutical company. \n\n\n  The ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2453088893","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453088893","pubTimestamp":1721829240,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pieris Pharmaceuticals shares doubled to $16.06 after the company said it was being bought by Palvella Therapeutics, a clinical-stage biopharmaceutical company.The combined company will focus on developing and commercializing Palvella's lead clinical product candidate, Qtorin 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations and other serious, functionally debilitating skin diseases.Upon completion of the proposed merger, the combined company will operate under the name Palvella Therapeutics, will be headquartered in Wayne, Pa., and is expected to trade on the Nasdaq Capital Market.In connection with the proposed merger, Palvella has secured commitments from a syndicate of leading healthcare-dedicated investors in an oversubscribed $78.9 million concurrent private financing.The combined company is expected to have $80.5 million of cash and cash equivalents at closing of the proposed merger. These cash resources are expected to be used to advance Qtor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","PIRS":"Pieris Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Palvella Therapeutics提出收购要约后Pieris Pharma股价翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PIRS":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n   Pieris Pharmaceuticals shares doubled to $16.06 after the company said it was being bought by Palvella Therapeutics, a clinical-stage biopharmaceutical company. \n\n\n  The combined company will focus on developing and commercializing Palvella's lead clinical product candidate, Qtorin 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations and other serious, functionally debilitating skin diseases. \n\n\n  Upon completion of the proposed merger, the combined company will operate under the name Palvella Therapeutics, will be headquartered in Wayne, Pa., and is expected to trade on the Nasdaq Capital Market. \n\n\n  In connection with the proposed merger, Palvella has secured commitments from a syndicate of leading healthcare-dedicated investors in an oversubscribed $78.9 million concurrent private financing. \n\n\n  The combined company is expected to have $80.5 million of cash and cash equivalents at closing of the proposed merger. These cash resources are expected to be used to advance Qtorin through multiple clinical data milestones and are expected to fund the combined company's operations into the second half of 2027. \n\n\n   The proposed merger is expected to close in the fourth quarter of 2024. Pieris stockholders are expected to own 18% of the combined company and pre-merger Palvella stockholders are expected to own 82% of the combined company \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 24, 2024 09:54 ET (13:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453088893"}